As a whole, DA‐mediated signaling at the astrocyte–microglial interface via DRDs appears as a pivotal counter‐regulatory system contributing to limit both Nrf2 and β‐catenin phosphorylation and subsequent degradation, thereby reinforcing the Nrf2‐ARE/Wnt/β‐catenin neuroprotective and immunomodulatory axis to combat aging and PD (Figure 7), and can be envisaged for the treatment of other CNS diseases. This evidence concerns the gene NFE2L2 and Parkinson disease.